Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Patisiran sodium is a double-stranded small interfering RNA (siRNA) that selectively targets a specific sequence within the transthyretin (TTR) messenger RNA (mRNA). By doing so, it effectively blocks the hepatic synthesis of both mutant and wild-type TTR. Patisiran sodium has significant applications in the field of hereditary TTR amyloidosis research.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | $ 827.00 | |
5 mg | Inquiry | $ 2,480.00 |
Description | Patisiran sodium is a double-stranded small interfering RNA (siRNA) that selectively targets a specific sequence within the transthyretin (TTR) messenger RNA (mRNA). By doing so, it effectively blocks the hepatic synthesis of both mutant and wild-type TTR. Patisiran sodium has significant applications in the field of hereditary TTR amyloidosis research. |
In vitro | Patisiran sodium induces degradation of transthyretin (TTR) through RNA interference, leading to decreased serum TTR protein levels and a reduction in tissue TTR protein deposits. It achieves this by selectively targeting a conserved sequence in the 3' untranslated region of both mutant and wild-type TTR messenger RNA[2]. |
Molecular Weight | N/A |
CAS No. | 1386913-72-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Patisiran sodium 1386913-72-9 inhibitor inhibit